Multitude Therapeutics’ AMT-676 Receives Breakthrough Therapy Designation from China’s CDE
On June 26, 2026, the Center for Drug Evaluation ( [&he…
U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253
On July 24, 2026, the U.S. Food and Drug Administr [&he…
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress
AMT-676 is a potential first-in-class CDH17-direct [&he…
Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
Download Full Poster (PDF) 112P – Phase I st [&he…
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation
December 17, 2025, according to the official website of…